Valuation: Avalo Therapeutics, Inc.

Market Cap 97Cr 84Cr 78Cr 72Cr 135.44Cr 9.22TCr 137.54Cr 920.83Cr 361.4Cr 4.59TCr 362.6Cr 354.63Cr 15TCr P/E 2026 *
-7.39x
P/E 2027 * -6.1x
Enterprise Value 55Cr 47Cr 44Cr 41Cr 77Cr 5.21TCr 78Cr 520.83Cr 204.41Cr 2.6TCr 205.09Cr 200.58Cr 8.7TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.28%
Yield 2026 *
0.06%
Yield 2027 * -
1 day-5.88%
1 week-1.03%
1 month-3.13%
3 months+33.11%
6 months+16.61%
Current year+0.50%
1 week 17.75
Extreme 17.75
19.97
1 month 17.54
Extreme 17.54
20.65
Current year 12.51
Extreme 12.51
24.27
1 year 7.87
Extreme 7.87
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap.
27/07/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
30/06/26 Free

Director

1,080 0.0020%
30/06/26 Fiscal year

Chief Technology Officer

13,962 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-1.56%-1.03%+131.31%-61.98% 97Cr
+2.35%+2.74%+38.10%+74.02% 5.65TCr
-3.19%-6.51%+25.66%+62.29% 5.36TCr
+0.42%+1.40%-15.61%-13.72% 2.29TCr
-0.62%-7.78%-9.28%+352.92% 2.14TCr
+0.15%+0.36%+24.28%-14.44% 2.03TCr
-1.69%-2.28%+31.86%-29.13% 1.76TCr
-1.45%-7.15%+17.96%+554.50% 1.47TCr
+3.41%-6.61%+162.81%+287.77% 1.35TCr
+0.28%-4.23%+42.32%+160.72% 1.33TCr
Average -0.71%-3.52%+44.94%+137.29% 2.35TCr
Weighted average by Cap. -0.01%-2.95%+30.59%+119.67%

Financials

2026 *2027 *
Net sales - -
Net income -8.57Cr -7.45Cr -6.94Cr -6.37Cr -12Cr -818.3Cr -12Cr -82Cr -32Cr -407.39Cr -32Cr -31Cr -1.37TCr -11Cr -9.6Cr -8.93Cr -8.2Cr -15Cr -1.05TCr -16Cr -105.31Cr -41Cr -524.74Cr -41Cr -41Cr -1.76TCr
Net Debt -42Cr -36Cr -34Cr -31Cr -59Cr -4TCr -60Cr -400.01Cr -156.99Cr -1.99TCr -157.51Cr -154.05Cr -6.68TCr -31Cr -27Cr -25Cr -23Cr -43Cr -2.91TCr -43Cr -291.04Cr -114.22Cr -1.45TCr -114.6Cr -112.08Cr -4.86TCr
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
03/26/03 $17.86 -2.14% 28,969
31/26/31 $18.25 -5.88% 9,23,877
30/26/30 $19.39 +2.00% 9,35,221
29/26/29 $19.01 -2.61% 7,89,787
28/26/28 $19.52 +0.10% 8,15,719
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
18.25USD
Average target price
44.69USD
Spread / Average Target
+144.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock